Wednesday, February 4, 2026 at 1:34 PM
AbbVie reported higher fourth-quarter revenue driven by strong demand for its immunology drugs Skyrizi and Rinvoq, while also experiencing a smaller decline in sales of its older drug Humira.
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.
Data sourced from public RSS feeds and News APIs.
